Premium
In multiple myeloma increased thrombopoietin (Tpo) production may be involved in the maintenance of platelet production
Author(s) -
Folman C. C.,
De Jong C. M.,
De Haas M.,
Von Dem Borne A. E. G. KR.
Publication year - 2001
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1034/j.1600-0609.2001.066005337.x
Subject(s) - thrombopoietin , platelet , medicine , haematopoiesis , bone marrow , multiple myeloma , endocrinology , thrombopoiesis , mean platelet volume , megakaryocyte , immunology , biology , stem cell , genetics
In multiple myeloma (MM), suppression of haematopoiesis occurs as a result of expansion of malignant cells in the bone marrow. Thrombopoietin (Tpo) levels in patients with impaired platelet production are generally found to be highly elevated. To examine the circulating Tpo levels in patients with MM, Tpo levels were measured in 50 serum samples from 34 patients. Tpo levels were subsequently related to disease stage, and cell numbers and markers, i.e. platelet count, leukocyte count and haemoglobin (Hb) concentration. Elevated Tpo levels were found in association with decreased platelet counts ( n =8), but also in patients with normal platelet counts ( n =14). The latter group included patients without and with signs of impaired haematopoiesis, i.e. with decreased Hb concentration and decreased leukocyte count. These results show that neither platelet counts nor Tpo levels are reliable parameters to judge bone‐marrow failure in patients with MM. Furthermore, in patients with MM, increased Tpo levels may play a role in the maintenance of thrombocytopoiesis. The origin of the increased Tpo levels remains to be determined.